The effect of SGLT2 inhibitors on UACR lowering has been consistently demonstrated, occurring in individuals with type 2 diabetes with preserved and impaired kidney function [6, 19], and tends to appear quickly after initiation of therapy, regardless of background therapy [6, 20]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.